胆固醇定和逻辑NIR-II探头用于三重响应性动脉样硬化成像
Qing-Qing Ye1, Han Zhu1, Liang Zhao1
1State Key Laboratory of Medicinal Chemical Biology, Frontiers Science Centre for New Organic Matter, Tianjin Key Laboratory of Biosensing and Molecular Recognition, Research Centre for Analytical Sciences, College of Chemistry, School of Medicine and Frontiers Science Center for Cell Responses, Nankai University, Tianjin 300071, P. R. China.
Analytical chemistry
|September 21, 2025
概括
一种新的基于胆固醇的探针NKH-CHOL,通过同时可视化脂质积累和氧化应激,可以早期检测动脉样硬化 (AS). 这种先进的成像工具为脆弱的斑块提供了更好的灵敏度,这对于预防心血管事件至关重要.
科学领域:
- 生物医学成像技术 生物医学成像技术
- 分子探头分子探头
- 心血管研究研究心血管研究
背景情况:
- 早期发现动脉样硬化 (AS) 对于预防心血管事件至关重要.
- 目前的成像技术缺乏对早期动脉样硬化斑块和微环境风险生物标志物的敏感性.
- 需要先进的分子工具,同时评估斑块脆弱性和脂质代谢.
研究的目的:
- 开发一种新的近红外II (NIR-II) 探测器NKH-CHOL,用于敏感的动脉样硬化的早期检测.
- 为了同步准富含脂质的微环境,感知斑块脆弱性的生物标志物.
- 为了使AS的脂质代谢障碍和氧化应激同时可视化.
主要方法:
- 开发NKH-CHOL,一种以胆固醇为的NIR-II探针,具有AND逻辑响应.
- 利用胆固醇定来精确定位并检测粘度/极性变化.
- 通过髓氧化酶活性感知高酸 (HClO) 的过度表达.
- 使用D-π-A结构的光体在特定条件下进行信号激活.
主要成果:
- 在AS小鼠模型中,NKH-CHOL实现了高对比度的动脉斑块成像.
- 探测器显示了AND逻辑反应,只有当粘度/极性扰动与HClO共存时才会激活.
- 生成的NIR-II发射 (>1000nm) 与超低背景.
- 成功地同时可视化了脂质代谢障碍和氧化应激.
结论:
- NKH-CHOL是第一个NIR-II分子工具,用于同时可视化脂肪代谢障碍和动脉样硬化中的氧化应激.
- 这种探测器通过提高成像灵敏度来解决早期AS检测的关键挑战.
- 对于推进心血管研究和临床诊断,NKH-CHOL具有显著的潜力.
相关概念视频
01:27Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
474
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
474
01:26Atherosclerosis III: Management
322
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
322
01:30Atherosclerosis I: Introduction
925
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
925
01:30Acute Coronary Syndrome III: Diagnostic Studies
218
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
218
01:23Atherosclerosis IV: Nursing Management
369
Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...
369